NCT04440436 - Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

June 4, 2022

Study Completion Date

June 4, 2035

Conditions

NHL

Interventions

DRUG

IM19 CAR-T Cells

"IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days"

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing